Related references
Note: Only part of the references are listed.Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
Howard Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
Lloyd E. Damon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P. Martin et al.
ANNALS OF ONCOLOGY (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
B. S. Kahl et al.
ANNALS OF ONCOLOGY (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
J Mangel et al.
ANNALS OF ONCOLOGY (2004)
Transplantation in patients with diffuse mantle cell lymphoma in first disease remission the prognostic value of β2-microglobulin and the tumor score
IF Khouri et al.
CANCER (2003)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni et al.
BLOOD (2003)
Outcome of autologous transplantation for mantle cell lymphoma:: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant registries
E Vandenberghe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
OM Howard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
